How Indian Broker Commission Compares to the UK, US and Singapore

Every Indian discussion of how brokers get paid eventually produces the same sentence: this is how it is done abroad. It is almost always said by someone who has picked one market, usually Britain, and generalised from it. That generalisation does not survive contact with the regimes themselves. Britain, the United States and Singapore each spent a decade or more arguing about intermediary pay, and each landed somewhere different, because each was answering a different question.

• Britain asked what the customer must be told, and answered with a disclosure regime that has widened steadily since.
• The United States asked whether the intermediary may be paid by the carrier for outcomes the client never sees, and answered in courtrooms and attorney-general settlements before regulators caught up.
• Singapore asked who the adviser actually works for, and answered by regulating the adviser's conduct and incentives directly.

India is asking a fourth question. It is not primarily regulating what the intermediary discloses, nor whom the intermediary serves. India regulates how much the insurer may spend in total, and lets each insurer's board divide that pool among its distributors. That is a different instrument pointed at a different actor, which is why foreign precedent is worth reading for the arguments rather than the settlements.

The Financial Conduct Authority regulates insurance distribution in the United Kingdom, and its instinct across two decades has been consistent: fix the information asymmetry and let the market price around it.

When the FCA's predecessor addressed commission on investment advice, the eventual answer was to sever the product provider from the adviser's pay altogether, so advice was bought by the client rather than funded by the manufacturer. General insurance was never taken that far, but the disclosure ratchet kept tightening. The European distribution rules the UK implemented before leaving required intermediaries to disclose the nature and basis of their remuneration, and to state whether they work on fee, on commission, or on some combination. Commercial customers acquired the right to ask what the broker was paid and get an answer.

The FCA also did something India has not: it ran market studies. It examined wholesale broking specifically, looked at how placement arrangements affect the price a client eventually pays, and published what it found. The regulator built an evidentiary picture of intermediary economics before deciding what to change, and in several cases decided that disclosure plus supervisory attention was change enough.

The British settlement is easy to misread as "the UK banned commission." It did not, not in general insurance; that ban applied to a different product universe. What the experience demonstrates is that disclosure alone does not compress remuneration; it relocates the argument. Once a commercial client knows the number, the number becomes negotiable. Firms with a defensible answer to "what did you do for this" kept their economics. Firms without one lost them to procurement. The reform did not set a rate. It changed who had to justify one.

The American structure confuses Indian readers because there is no American insurance regulator. Insurance is regulated by the states, each licensing its own producers and writing its own rules, loosely coordinated through model laws that states adopt, amend or ignore. There is no national commission rule to compare to an IRDAI regulation.

The fight that defined US broker remuneration therefore began not with a regulator but with the New York Attorney General's investigation into contingent commissions in 2004: payments made by insurers to brokers based not on the individual placement but on the aggregate volume, retention or profitability of the book the broker steered to that insurer. A broker holding a client's mandate to find the best terms had, simultaneously, a financial interest in where the business landed, and in the worst instances the placement process had been arranged to produce a predetermined result.

The largest brokers settled and stopped accepting contingent compensation on the affected lines. The middle market never made that concession. Then the ground shifted again: years later the restrictions were relaxed, and contingent compensation returned under disclosure obligations rather than prohibition. New York, the state that prosecuted the original case, ended up with a producer-compensation disclosure rule instead of a ban.

So the American arc runs: prohibition by settlement, then partial restoration under disclosure. The market did not conclude that volume-linked insurer payments to intermediaries were intolerable. It concluded they were tolerable if visible and if the mandate was honest.

The Monetary Authority of Singapore supervises insurers and intermediaries in a market small enough that the regulator can be granular, and it used that granularity differently from Britain or America. Its distribution review in the early 2010s produced a package aimed at the adviser rather than at the payment:

1. Raise the entry bar. Competence and qualification standards for representatives, on the theory that mis-selling is partly a capability problem and not only an incentive problem.
2. Score conduct, not just sales. Pay for representatives and their supervisors was tied to a balanced assessment weighting how business was written, not merely how much. A representative whose files showed poor suitability documentation, or whose clients lapsed early, took a pay consequence.
3. Spread the payment across the life of the contract on long-tenure products, so the adviser's income persisted only if the policy did.
4. Build a no-advice, no-commission channel for buyers who knew what they wanted, removing distribution cost from the product rather than arguing about how to divide it.

Singapore treated remuneration as an input to conduct supervision rather than as a market-structure problem in its own right. The pay design existed to make the conduct standard enforceable.

That is the regime India's reported reform ideas most resemble. The July 2026 reporting describes IRDAI weighing staggered or trail structures spread over the policy life, and a distinction between distributors who advise, document and support claims and distributors (banks were the example given) that attach insurance to another transaction. Both ideas are Singaporean in spirit. Neither is a rule. The consultation paper had not been published as of the date of this post, and every idea attributed to it remains a proposal reported in the press.

Britain, America and Singapore all regulate at the point of the intermediary: what it must tell the client, what it may accept, how its pay must be shaped. India, since April 2023, does something else. The IRDAI (Payment of Commission) Regulations, 2023 removed product-wise commission caps and moved the decision into each insurer's board-approved commission policy. That policy is bounded by the IRDAI (Expenses of Management, including Commission, of Insurers) Regulations, 2024, effective 1 April 2024, capping an insurer's aggregate expenses at roughly 30 percent of gross written premium for general insurers and roughly 35 percent for standalone health insurers.

Read that mechanism carefully. It does not say what a broker may be paid on any policy. It says what the insurer may spend across everything, and leaves the board to allocate the pool. The regulated party is the carrier; the intermediary is downstream of a constraint aimed at somebody else. The consequences are not the ones any foreign regime produced:

• Commission becomes a queue, not a rate. When the envelope tightens, every distributor competes against every other, and against the insurer's own advertising, technology and staff costs, for room under one ceiling. A broker can be repriced by an insurer's decision about something unrelated to broking.
• The negotiation is bilateral and invisible. Nothing here requires the client to be told the number.
• Reform arrives at the insurer first. The Sabka Bima Sabki Raksha (Amendment of Insurance Laws) Act, 2025, in force from 5 February 2026, restored IRDAI's statutory power to cap distributor commissions. The Act imposes no cap. Any cap made under it would still be a rule about payment, not about disclosure.

The comparison is not India versus the UK on rate. It is India regulating spend, Britain regulating information, America regulating conflict, Singapore regulating conduct.

The Indian commercial reality is more moderate than the reform conversation implies, because the public argument is being conducted on retail life numbers.

On commercial placements, grid rates for property and engineering lines run roughly 7 to 12.5 percent, and liability lines roughly 10 to 15 percent. Realised yields, after the account-level negotiation that actually determines outcomes, sit lower: 8 to 10 percent on large risks, 12 to 15 percent on mid-market package business, 15 to 20 percent on retail health and miscellaneous retail where variable components are included.

Set against that: up to roughly 40 percent of premium is reported, in the July 2026 press coverage, as achievable on some life and health products, substantially paid at the point of sale. That figure is an observed market level, not a cap and not a commercial-lines number.

The divergence that should worry a commercial broker is different: non-life commission expense reached roughly INR 47,266 crore in FY2024-25, up close to 19 percent, while general insurance premium grew about 8.5 percent. Distribution cost outgrew the premium base it is paid from, inside a fixed envelope. That gap is what makes an insurer's board look for room, and it is the pressure a commercial broker feels first.

The honest inventory.

Transfers well.

• The disclosure argument is unwinnable in the long run, so pre-empt it. All three markets ended with more remuneration visibility than they started with, whichever route they took. None reversed. A firm that treats its number as defensible on request has time to make it defensible; a firm that treats it as confidential is scheduling a worse conversation for later.
• Justified work survives; unjustified work gets procured away. The British experience is unambiguous and the Singaporean design assumes it.
• Conflicts are tolerable when disclosed and fatal when discovered. The American arc is the cleanest demonstration available.

Transfers badly.

• Rate benchmarks. Foreign commission levels reflect foreign product mixes, expense structures, tax and claims economics. A percentage lifted from one market into an Indian negotiation is noise dressed as evidence.
• The mechanism itself. Britain's disclosure duties bite on the intermediary. India's expense ceiling binds the insurer. Importing a rule that constrains a party India does not constrain produces a proposal that cannot be implemented in the Indian instrument set.

The most useful transferable insight is negative: no market that regulated intermediary pay achieved its stated objective through the pay rule alone. Britain needed supervision behind disclosure. America needed disclosure behind the settlements. Singapore built pay design as scaffolding for a conduct standard. Any Indian rule that changes the shape of commission without changing what is measured, evidenced and supervised will change the shape of commission and nothing else.

Two preparations follow before the paper lands. Build the realised-yield table now, by line and segment: whichever direction reform takes, the first question anyone asks is what the firm actually earns, and grid rates are not the answer. Then watch the envelope rather than the rate, because knowing which carriers sit near their ceiling is more predictive than reading the consultation coverage.

India is arriving late at questions others have already litigated. Arriving late is an advantage only for a firm that has read the transcripts.